Search Results for:
-
BioWorld Stock Report For Public Biotechnology Companies
-
Stock Gainers and Losers For The Week
-
Money Raised By Biotech: Jan. 1 - May 16, 2013
-
Money Raised By Biotech In 2013 vs. 2012
-
Biotech Collaborations Between Pharmaceutical & Miscellaneous Companies: April 1 - May 16, 2013
Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date APRIL Actavis Inc. (Parsippany, N.J.) Valeant Pharmaceuticals International Inc. (Aliso Viejo, Calif.) ND Agreement for Actavis to be the exclusive marketer and distributor of an authorized generic of Valeant's Zovirax ointment Terms were not disclosed 4/8/13 Bial SA (S. Mamede do Coronado, Portugal) Ono Pharmaceutical Co. Ltd. (Osaka, Japan) ND Exclusive license agreement for the development and -
Biotech - Big Pharma Collaborations: Modified And Terminated Agreements: April 1 - May 16, 2013
Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date I. Modified Agreements APRIL Affymax Inc. (Palo Alto, Calif.) Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) $180 Amended collaboration for Omontys, changing the deal from a profit-sharing arrangement to a milestone and royalty-based compensation structure to Affymax Takeda assumes full responsibility for Omontys and, if it reintroduces the drug to market, Affymax would be eligible to receive royalties and -
Manufacturing, Marketing And Distribution Agreements Between Biotech And Pharmaceutical Companies: April 1 - May 16, 2013
Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date APRIL Aeterna Zentaris Inc. (Quebec City) Ergomed Clinical Research Ltd. ND Co-development and profit-sharing agreement for AEZS-108 in endometrial cancer Ergomed will receive a single-digit percentage of any net income received by Aeterna Zentaris in that indication, up to a specified maximum amount 4/11/13 Aeterna Zentaris Inc. (Quebec City) Merck KGgA (Darmstadt, Germany) subsidiary ND Deal for manufacturing -
Collaborations Between Biotech And Pharmaceutical Companies: April 1 - May 16, 2013
Total Value in 2013: $6,192M* Number of Deals in 2013: 97 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date APRIL Alchemia Ltd. (Brisbane, Australia) AstraZeneca AB (Sodertalje, Sweden; unit of AstraZeneca plc) $240 Deal for Alchemia's Diversity Scanning Array and Versatile Assembly on Stable Templates technologies to discover and develop small molecules for multiple targets in the oncology, respiratory, cardiovascular, metabolism, infection and neuroscience -
Gilead Data Suggest Targeted Cancer Drugs Coming of Age
Gilead Science Inc.'s oral targeted cancer drug, idelalisib (GS-1101), made a splash last week when the American Society of Clinical Oncology (ASCO) unveiled thousands of abstracts scheduled for presentation at next week's annual meeting in Chicago. In a press conference Wednesday afternoon, Jennifer R. Brown, director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute, provided Phase I findings suggesting idelalisib, as a single agent, has the potential to stave off -
Top 10 Bio/Pharma Deals: 2013
Company Company Deal Value Inspiration Biopharmaceuticals Inc. Baxter International Inc. $700M Chiasma Inc. Roche AG $595M Edison Pharmaceuticals Inc. Dainippon Sumitomo Pharma Co. Ltd. $545M Trevena Inc. Forest Laboratories Inc. $460M Abide Therapeutics Inc. Merck & Co. Inc. $430M Moderna Therapeutics Inc. AstraZeneca plc $420M Isis Pharmaceuticals Inc. Roche AG $393M Ambrx Inc. Astellas Pharma Inc. $300M Resolve Therapeutics LLC Takeda Pharmaceutical Co. Ltd. $255M Alchemia Ltd. AstraZeneca -
Mirna Puts First MicroRNA Mimic into the Clinic
Mirna Therapeutics Inc. announced last week that it has initiated a Phase I trial of MRX34, its microRNA (miRNA) mimic. Andreas Bader, director of research at Mirna, told BioWorld Insight the company believes it's the first miRNA mimic to enter the clinic. Strictly speaking, it's not the first drug in the clinic involving a miRNA. That distinction belongs to Santaris Pharma A/S, which has been in the clinic since 2008 with miravirsen (SPC3649), its inhibitor of miR-122, a liver specific miRNA -
Week in Washington
Amending an oversight in the Jumpstart Our Business Startups (JOBS) Act, the House voted 416-6 to set a deadline for the SEC to implement Regulation A changes. The National Institutes of Health's Office of Biotechnology Activities is proposing a revision to its guidelines for research involving recombinant or synthetic nucleic acid molecules. Under the proposal, as long as an initial human study of certain human gene transfers is approved by a registered institutional biosafety committee (IBC -
Bench Press: BioWorld Looks at Translational Medicine
Why PARP Inhibitors Kill BRCA Mutants Inhibitors of the enzyme poly(ADP-ribose) polymerase (PARP) selectively kill cells with BRCA mutations, and researchers at the University of Michigan have discovered one reason that they do so. In their studies, the authors showed that poly(ADP-ribose) (PAR) recruits BRCA1, in complex with the protein BARD1, to sites of DNA damage. When PAR polymerization is inhibited, such binding cannot occur, and BRCA1 cannot be recruited to repair DNA damage. Many BRCA1 -
Stock Movers
-
As Markets Fancy Biotech, PTC Therapeutics Joins IPO Queue
PTC Therapeutics Inc. made last week a biotech trifecta for initial public offerings (IPO), filing an S-1 with the SEC seeking to raise up to $85 million. Earlier, gene therapy firm bluebird bio Inc. and Esperion Therapeutics Inc., a company working on a drug to lower LDL-cholesterol, joined the IPO queue. PTC, which filed as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, plans to list its common stock on the NASDAQ Global Market under the symbol "PTCT." The -
Other News To Note
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., said preclinical data showed that RNAi therapeutics targeting ALAS-1 (aminolevulinate synthase-1) can completely block the abnormal production of toxic intermediates of the heme biosynthesis pathway that cause the symptoms and disease pathology of acute intermittent porphyria (AIP). Data were presented at the International Congress of Porphyrins and Porphyrias in Lucerne, Switzerland. Alnylam is developing ALN-AS1 as part of its "Alnylam 5x15 -
Sepsis Patients May Need Bigger Immune Response
Through the indirect targeting of toll-like receptors via their co-receptor, researchers have boosted the immune response to infection, and helped animals with experimentally induced sepsis fight off the bacteria that set off the septic response. Given that one effect of sepsis is massive hyperinflammation, the notion of helping sepsis patients by boosting their innate immune response might seem counterintuitive at best, or like the punch line of a bad mother-in-law joke, at worst. But the -
Oncos Targets Solid Tumors With Oncolytic Virus Approach
Taking an inventive route to drug development, Oncos Therapeutics Ltd. has its roots in a type of compassionate use program that was started in 2007 at the international comprehensive cancer center, Docrates, in Helsinki, Finland. The Advanced Therapy Access Program for experimental treatments with the company's oncolytic viruses was made possible through European Union (EU) regulation EC/1394/2007, designed to improve safe access by patients across the EU to gene therapy, somatic cell therapy -
Pharma: Other News To Note
Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs. Mylan Inc., of Pittsburgh, said its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. Mylan Pharmaceuticals received final approval from -
Appointments and Advancements
Aeterna Zentaris Inc., of Quebec City, added Marcel Aubut, David A. Dodd, José P. Dorais, Carolyn Egbert, Juergen Ernst, Pierre Lapalme and Gérald Limoges to its board. AltheRx Pharmaceuticals Inc., of Exton, Pa., named Jim Bennethum CEO, appointed Charles E. Becker board chairman and named Jeffrey O'Donnell and Anthony Zook to its new board of directors. BG Medicine Inc., of Waltham, Mass., appointed Paul Sohmer president and CEO. Biota Pharmaceuticals Inc., of Rockville, Md., added Anne
Category
Current Filters
- xNOT stem cells
Related Keywords
Categories
- x BioWorld Today (35527)
- x BioWorld International (6647)
- x BioWorld Insight (5930)
- x Bioscan (2259)
- x Bio Perspectives (1065)
- x BioWorld Phase III Report (626)
- x State of the Industry Report (475)
- x BioWorld Genomics Review (471)
- x Executive Compensation Report (255)
- x Top 25 Drug Report (153)
- x Biotech Innovations (64)
- x BioWorld Snapshots (42)
- x Market-Leading Biotech Drugs (27)
- x RNAi Report (17)
- x Recorded (17)
- x Featured (7)
- x MDD (6)
- x BioWorld Executive Compensation Report 2013 (1)
- x Upcoming (1)
- x BioWorld Today (1)